Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Wuhan Healthgen Biotechnology Quick Ratio?
Wuhan Healthgen BiotechnologySHSE:688765 +4.66%19 Quick Ratio is 3.06 as of Mar. 2026, which is 65% above its 10-year median of 1.86. GuruFocus rates SHSE:688765 with a GF Score™ of 19/100. The stock has 7 warning signs investors should review. Among 999 Drug Manufacturers companies, Wuhan Healthgen Biotechnology ranks better than 76.68% on this metric.
Wuhan Healthgen Biotechnology has a quick ratio of 3.06. It generally indicates good short-term financial strength.
The historical rank and industry rank for Wuhan Healthgen Biotechnology's Quick Ratio or its related term are showing as below:
SHSE:688765'
s Quick Ratio Range Over the Past 10 Years
Min: 0.36 Med: 1.86 Max: 8.73
Current: 3.06
During the past 12 years, Wuhan Healthgen Biotechnology's highest Quick Ratio was 8.73. The lowest was 0.36. And the median was 1.86.
SHSE:688765's Quick Ratio is ranked better than 76.68% of 999
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs SHSE:688765: 3.06
Wuhan Healthgen Biotechnology (SHSE:688765) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Wuhan Healthgen Biotechnology Quick Ratio Related Terms
Wuhan Healthgen Biotechnology Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Wuhan Healthgen Biotechnology's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wuhan Healthgen Biotechnology Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Wuhan Healthgen Biotechnology's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Wuhan Healthgen Biotechnology's Quick Ratio falls into.
Wuhan Healthgen Biotechnology Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wuhan Healthgen Biotechnology (SHSE:688765) has a Quick Ratio of 3.06 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Wuhan Healthgen Biotechnology and its competitors. This is 65% above median its historical median of 1.86. Over the past decade, Wuhan Healthgen Biotechnology's Quick Ratio has ranged from 0.36 to 8.73. According to the industry distribution chart, Wuhan Healthgen Biotechnology ranks #233 out of 999 companies in the Drug Manufacturers industry, placing it in the top 23.3%.
Is Wuhan Healthgen Biotechnology's Quick Ratio too high?
Wuhan Healthgen Biotechnology's current Quick Ratio of 3.06 is 65% above median its 10-year median of 1.86. Over the past 10 years, this metric has ranged from a low of 0.36 to a high of 8.73. The Drug Manufacturers industry median Quick Ratio is 1.45. Wuhan Healthgen Biotechnology's value of 3.06 is 111% above this industry median. Based on the distribution chart, Wuhan Healthgen Biotechnology ranks #233 out of 999 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Wuhan Healthgen Biotechnology has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Wuhan Healthgen Biotechnology's Quick Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Wuhan Healthgen Biotechnology ranks #233 out of 999 companies for Quick Ratio. This places Wuhan Healthgen Biotechnology in the top 23% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 1.45. Wuhan Healthgen Biotechnology's value of 3.06 is 111% above this benchmark. Historically, Wuhan Healthgen Biotechnology's own Quick Ratio has ranged from 0.36 to 8.73 over the past decade. While the company's 10-year median is 1.86 vs. the industry median of 1.45, Wuhan Healthgen Biotechnology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 999 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wuhan Healthgen Biotechnology's current Quick Ratio of 3.06 is 111% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Wuhan Healthgen Biotechnology and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wuhan Healthgen Biotechnology's current Quick Ratio is 3.06, which is 65% above median its own 10-year median of 1.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuhan Healthgen Biotechnology stock overvalued right now?
Wuhan Healthgen Biotechnology (SHSE:688765) has a current Quick Ratio of 3.06. The current Quick Ratio is 3.06, which is 65% above median its 10-year median of 1.86 and 111% above the Drug Manufacturers industry median of 1.45. Wuhan Healthgen Biotechnology's overall GF Score™ is 19/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Wuhan Healthgen Biotechnology (SHSE:688765), the current Quick Ratio is 3.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Wuhan Healthgen Biotechnology Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688765 has been successfully added to your 
